Recent investigations have converged on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and dopaminergic signaling. While GIP agonists are commonly employed for managing type 2 diabetes mellitus, their potential effects on motivation circuits, specifically governed by dopaminergic pathways, are